Drug production in Moscow has grown by 7.2 percent over six months

From January through June 2025, Moscow companies produced 7.2 percent more drugs than in the same period last year. The news was reported by Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry.

Earlier, the Mayor of Moscow reported on the growth of production of pharmaceutical substances in the capital. In the first half of 2025, the output of drug components almost doubled compared to the same period last year.

“On the instructions of Sergei Sobyanin, the city is actively developing the medical industry. Thanks to the support measures, enterprises are modernizing production and expanding their range of critical products. For example, from January through June 2025, companies produced 7.2 percent more drugs than in the same period last year. In particular, almost 2.6 million packages of anticancer drugs and immunomodulators were produced, as well as 2.6 million packages of drugs for the treatment of respiratory system organs,” Maxim Liksutov said.

In the first half of 2025, the production of anticancer drugs and immunomodulators increased by a factor of 1.6, and drugs for the treatment of the respiratory system by 25.9 percent.

“Today, more than 300 enterprises in Moscow provide the country’s residents with medicines and medical devices. Products made by Moscow companies are in high demand both in the domestic and foreign markets. Thus, from January to June of this year enterprises produced medicines worth 37.1 billion rubles,” said Anatoly Garbuzov, Minister of the Moscow Government, Head of the Moscow Department of Investment and Industrial Policy.

In the first half of 2025, the Zelenograd production site of the Binnopharm Group produced more than three million packages of pharmaceuticals, 24 percent more than in the same period of 2024. This significant growth is largely due to the efficient management of production and logistics processes. There was also a considerable increase in the size of the export market. In January-June 2025, 2.6 times more products intended for export were produced than in the first six months of 2024. The key factors in this growth were the scaling up of production of drugs for the treatment of chronic respiratory diseases (including aerosol drugs) and increased capacity utilization.

According to Anatoly Yaglenko, Corporate Director for Production, the site will continue systematic work aimed at increasing production of drugs, focusing on stable demand both in Russia and abroad. The increase in volume in the first half of the year is the result of the introduction of new technological processes and optimization of existing production lines. Systematic work to increase on efficiency allowed the company to significantly increase the volume of output and shorten the production cycle.

Earlier this year, the pharmaceutical company confirmed its status as an industrial complex. This will enable it to optimize costs and invest the saved funds in the development, modernization and expansion of production operations. Thus, for an enterprise, the real estate tax will be 50 percent of the standard rate, and the land lease rate will be 0.3 percent of the cadastral value of the plot.

The company also benefits from a preferential investment loan at a reduced rate of three percent per annum from the Moscow Fund for Support of Industry and Entrepreneurship. The enterprise will be able to reconstruct its premises and acquire a new production line, which will allow it to launch the production of socially important drugs.

Another company in the capital, NovaMedica, develops and manufactures drugs. The company’s production and research facilities are located in the Moscow Technopolis special economic zone. The key area of the company’s product development is neurology, including diseases of the central nervous system, which is why the search for effective new solutions is of high social significance.

The Moscow enterprise MosPharma produces more than 80 types of products, including drugs for applications in the fields of neurology, gastroenterology, pediatrics, dentistry, dermatology and other fields. It has also launched industrial-scale production of homeopathic remedies, herbal medicines, and food supplements. The company also manufactures medical devices, oral hygiene and cosmetics products.